4.7 Article

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

期刊

CLINICAL CANCER RESEARCH
卷 18, 期 9, 页码 2478-2489

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-2614

关键词

-

类别

资金

  1. Department of Defense [PR101053]
  2. Mesothelioma Applied Research Foundation (MARF)
  3. Commonwealth Foundation for Cancer Research
  4. Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center
  5. American Association for Thoracic Surgery (AATS)
  6. IASLC-International Association for the Study of Lung Cancer
  7. National Lung Cancer Partnership/LUNGevity Foundation
  8. Stony Wold-Herbert Fund, New York State Empire Clinical Research Investigator Program (ECRIP)
  9. National Cancer Institute [U54CA137788/U54CA132378]

向作者/读者索取更多资源

Purpose: Mesothelin (MSLN) is a tumor-associated antigen, being investigated as a biomarker and therapeutic target in malignant pleural mesothelioma (MPM). The biologic function of MSLN overexpression in MPM is unknown. We hypothesized that MSLN may promote tumor invasion in MPM, a tumor characterized primarily by regional aggressiveness and rare distant metastases. Experimental Design: Human and murine MPM cells with MSLN forced expression and short hairpin RNA knockdown were examined for proliferation, invasion, and matrix metalloproteinase (MMP) secretion. The influence of MSLN overexpression on MPM cell invasion was assessed in an orthotopic mouse model and in patient samples. Results: MSLN expression promotes MPM cell invasion and MMP secretion in both human and murine MPM cells. In an orthotopic MPM mouse model characterized by our laboratory, MPM cells with MSLN overexpression preferentially localized to the tumor invading edge, colocalized with MMP-9 expression, and promoted decreased survival without an increase in tumor burden progression. In a tissue microarray from epithelioid MPM patients (n = 139, 729 cores), MSLN overexpression correlated with higher MMP-9 expression at individual core level. Among stage III MPM patients (n = 72), high MSLN expression was observed in 26% of T2 tumors and 51% of T3 tumors. Conclusions: Our data provide evidence elucidating a biologic role for MSLN as a factor promoting tumor invasion and MMP-9 expression in MSLN expressing MPM. As regional invasion is the characteristic feature in MSLN expressing solid cancers (MPM, pancreas, and ovarian), our observations add rationale to studies investigating MSLN as a therapeutic target. Clin Cancer Res; 18(9); 2478-89. (C) 2012 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据